XRTX - XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023 | Benzinga
? Preclinical Findings Help Clarify and Reinforce the Role of Uric Acid in the Pathogenesis of Polycystic Kidney Disease and the Potential of XORTX's Proprietary Formulation of Oxypurinol as a Treatment Option for Autosomal Dominant Polycystic Kidney Disease ?
CALGARY, Alberta, Nov. 02, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the presentation of new research findings at the American Society of Nephrology meeting being held November 3, 2023 in Philadelphia. The abstract entitled "The Effect of Lowering Uric Acid with a Xanthine Oxidase Inhibitor on PKD in Mice" was reviewed by the ASN review panel for scientific merit and novel discoveries. The studies were conducted at the University of Colorado in the independent laboratory of Dr. Charles Edelstein and were sponsored by XORTX. The studies will be presented at Kidney Week during the Session Title: Genetic Diseases: Cystic - Therapeutic Investigations and Prognosis, November 2, 2023.
This poster reports amalgamated results of studies in either rat and mouse models of polycystic kidney disease ("PKD") challenged with low to moderate circulating uric acid. The effect of increased uric acid on cyst growth – kidney size - and kidney function, as well as inflammatory markers was measured. The effect of xanthine oxidase inhibition with XORTX's proprietary formulation of oxypurinol was also characterized and quantified.
Upon analysis, results of the studies support the conclusion that moderate soluble, but not saturating, circulating uric acid can:
1/ accelerate kidney expansion rate and worsen kidney function;
2/ be a mechanism of kidney injury in Autosomal Dominant Polycystic Kidney Disease ("ADPKD") even in the absence of uric acid crystal formation; and
3/ be associated with increased pro-inflammation cytokines.
The results notably also support the finding that a threshold of xanthine oxidase inhibition / uric acid lowering may be predictive of an optimal therapeutic benefit for patients with ADPKD and accompanying hyperuricemia.
Dr. Allen Davidoff commented, "The results of these studies suggest that management of xanthine oxidase activity in PKD may be more important than previously appreciated. Moreover, previously unrecognized factors related to diet, genetic factors or prescribed ...